Particular frequency changes can be used in animals and humans based on the CATEEM® technology with its pre-defined frequency ranges. Therefore quantitative EEG is a translational tool to follow time and dose dependent actions of synthetic drugs and/or plant derived extracts, as drug-induced spectral signatures can be found in the human EEG.

The NeoCATEEM contains EEG’s from several hundred normal healthy people and is used to discover deviations in terms of increased or decreased spectral power at particular electrode positions.




 Electropharmacogram in the rat: Four semi-microelectrodes are fixed to skull and allow quantitative-topological EEG with specified receptor determination after drug application. Electropharmacograms can be compared to the existing Neo-Cateem database to 200 different drugs in different dosages – acting on acetylcholine, norepinephrine, serotonine, dopamine, glutamate and GABA neurotransmitters. New data is screened for similarities among frequency segments and generates a list showing corelation index with statistical probability. Quantitative EEG is therefore useful for

  • Treatment effect detection
  • dose dependency of action
  • classification of compounds
  • transmitter detection of drugs



The Neo-Cateem database consist of 30 000 hours of recording of more than 200 chemicals and drugs with at least 3 dosages, including:

  • anesthetics
  • analgesics
  • antidepressives
  • neuroprotectives
  • antidementives
  • antiepileptics
  • hallucinogenics
  • neuroleptics
  • stimulants

The image to the right shows time dependent effects of scopolamine at 0,5 mg/kg administered i.p. to the rat.

You may not be able to visit this page because of:

  1. an out-of-date bookmark/favourite
  2. a search engine that has an out-of-date listing for this site
  3. a mistyped address
  4. you have no access to this page
  5. The requested resource was not found.
  6. An error has occurred while processing your request.


Please try one of the following pages:

NeuroScios is capable of handling all safety imaging for neurological trials.

In general the most frequent neurological drug safety issues involve infarcts, haemorrhages, ARIA-H (micro-haemorrhages), ARIA-E (Vasogenic Edema), or issues with the BBB.

Safety imaging takes place at certain predefined timepoints during the trial, as several of the occurring AE’s will show limited (or no clinical significant signs at all) during physical examination. Early detection by Imaging prevents that a condition suddenly appears as a late finding at clinical tests with the risk of permanent damage. Early discovery by Imaging and a timely dose-stop can possibly prevent that trial subjects are dosed while actually having a serious adverse event.

NeuroScios has several experts that will make sure that the “Imaging” paragraph on a clinical trial protocol will follow regulatory guidance.

In addition to consultancy NeuroScios can also support a trial with giving guidance to local Radiologists about the set-up and review of neuroscience imaging.

As a complete service, NeuroScios offers to handle Central Reading of clinical trial neuroscience imaging, with reports to sites and/or safety committees.

The use of Radiologic Imaging in the subject screening period is significantly increasing, as there are benefits that deliver a return on this investment and regulatory agencies have issued guidance to protect potential subjects who might appear to have an increased risk for side effects.

  • Trial enrichment  (e.g. enrol subjects with a certain disease stage which is expected to respond (faster or statistically more sound) to the drug.

    Example: Enrolment of subjects for which the hippocampus size and cognitive test show the required evidence for an AD Trial.

  • Exclusion of diseases clinically mimicking the target disease, but which are expected to show no effects from the investigational drug.

    Example for AD: Exclude vascular dementia / heavy load of WM damage.

  • Exclusion of patients/subjects who might suffer from an increased safety risk

    Example: Subjects with micro-haemorrhages prior to trial entry might have an increased risk of (new) haemorrhages in the brain. The current FDA guideline allows subjects to have a cut-off maximum of 4 micro-haemorrhages in the brain for a AD trials with amyloid targeting drugs, 5 micro-haemorrhages leads to exclusion.

This detailed screening guideline makes independent consistent reading extremely important. The quality of the reading is highly depending on the choice and quality of the MRI sequences. NeuroScios knows exactly what it takes to do this.

Exact rules and consistent application of those rules for Screening are extremely important. Just the practical topic with exclusion because of benign space occupying lesions already requires a lot of attention and suffers for locally varying interpretations.



Commonly used Imaging modalities/biomarkers in neuroscience are MRI & PET.

  • Primary endpoints

  • Secondary endpoints, or selected group review

  • Proof of Concept or Proof of Principle situations

This PoC/PoP category is getting a lot of attention, as for some investigational drugs the exact response of tissue and disease is not fully researched.

This PoC/PoP category is getting a lot of attention, as for some investigational drugs the exact response of tissue and disease is not fully researched.   
Connected to the PoC / PoP category is also the use of investigational imaging techniques which require a lot of attention with regard to standardised production, QA, QC of data and central reading. Connected to the PoC / PoP category is also the use of investigational imaging techniques which require a lot of attention with regard to standardised production, QA, QC of data and central reading. NeuroScios offers a wide range of support with regard to this category.

Biomarker modalities

have several techniques that are tailored to the expected treatment response.

PET Examples for Alzheimer’s Disease:

  • FDG PET                      

  • PIB PET or other PET Amyloid biomarkers      


In biomarker MRI for Alzheimer’s Disease,

the most favourite sequence is the 3DT1 sequence. With a properly acquired 3DT1 sequence a wide selection of brain volume data can be generated. It’s however extremely important that the 3DT1 sequence is exactly done as required, the challenge is that the requirements vary per MRI scanner vendor & type.

Phantom Imaging plays an important role in the Quality Assurance of Biomarker MRI sequences.                  

Data based on the 3DT1 sequence*: Whole Brain Volume (WBV), Ventricular Volume (VV), Hippocampal Volume (HV) and Amygdala Volume (AV), Entorhinal Cortex volume (ERC)                                         







Dec. 2013

COO, NeuroScios GmbH

Oct. 2013 - Dec. 2013

Head of Clinical Operations, AXON Bratislava

2012 - 2013

Director Clinical Department, QPS-Austria

2011 - 2012

Deputy Director, Clinical Department at JSW-Lifesciences GmbH, Grambach, Austria

2008 - 2011

Clinical Research Associate and Project Manager at JSW-Lifesciences GmbH, Grambach, Austria

2004 - 2008

Medical representative, Novartis Consumer Health Gebro GmbH in Fieberbrunn, Austria

2001 - 2004

Family induced stay in the USA

1993 - 2001

Medical representative, Novartis Consumer Health Gebro GmbH in Fieberbrunn, Austria

1992 – 1993

Environmental referee, Graz, Austria

1991 - 1992

Parental leave

1989 - 1992

Managing director, Pro Scientia, Otto Mauer Fonds, Forum St. Stephan and Commission of Education, Vienna, Austria


Research Trainee, Slaughterhouse Graz, “Extraction of Hyaluronic Acid from eyes”, Graz, Austria


2011 - 2013

Project Management

Phase II, MCI 12 sites international

2010 - 2012

Regulatory Affairs, Monitoring, 2 Sites in Austria

Phase III, Cystic Fibrosis

2009 - 2013

Medical Writing (Protocol, Informed Consent), Project Management, Regulatory Affairs

Phase II, Alzheimer’s Disease (18 sites international)

2009 - 2012

Monitoring, 1 site in Austria

Phase III: Acute Ischemic Stroke, (ICU)

2009 - 2011

Project Management, Regulatory Affairs

Phase II: Alzheimer’s Disease

Project Management, Regulatory Affairs

NIS; Treatment of COPD II GOLD Classification

2009 - 2009

Regulatory Affairs, 1 site, Austria

Phase I, Tetracycline

2008 - 2009

Monitoring, 1 site, Austria

Phase II, Pulmonary Arterial Hypertension

Monitoring, Regulatory Affairs, 4 sites, Austria

Phase III, Thromboembolism

Monitoring, Regulatory Affairs, 2 sites, Austria

Phase III, Secondary Prevention of Venous Thromboembolism

Monitoring, 2 sites, Austria

Phase III, Acute Symptomatic Venous Thromboembolism


February 2014

Medical and Nutrition Consulting GmbH, Last Online GCP Training


Professional qualification as medical representative

1987 - 1989

Study of chemistry, Technical University Graz, Austria


Ph.D.graduation (Zoology and biochemistry, Karl-Franzens-University Graz, Austria)


MS Project, Access, Publisher, PowerPoint, Excel, Word









gem. § 25 Mediengesetz sowie Anbieteridentifizierung gem. § 5 Abs 1 ECG


Medieninhaber, Herausgeber, Hersteller und Redaktion:

NeuroScios GmbH
Neuroscience Optimized Solutions

Willersdorferstrasse 7
A-8061 St.Radegund/Graz

Mobil: +43 (0) 664 888 699 01
email: This email address is being protected from spambots. You need JavaScript enabled to view it.


Haftung für Inhalte

Die Inhalte unserer Seiten wurden mit größter Sorgfalt erstellt. Für die Richtigkeit, Vollständigkeit und Aktualität der Inhalte können wir jedoch keine Gewähr übernehmen. Als Diensteanbieter sind wir gemäß § 7 Abs.1 TMG für eigene Inhalte auf diesen Seiten nach den allgemeinen Gesetzen verantwortlich. Nach §§ 8 bis 10 TMG sind wir als Diensteanbieter jedoch nicht verpflichtet, übermittelte oder gespeicherte fremde Informationen zu überwachen oder nach Umständen zu forschen, die auf eine rechtswidrige Tätigkeit hinweisen. Verpflichtungen zur Entfernung oder Sperrung der Nutzung von Informationen nach den allgemeinen Gesetzen bleiben hiervon unberührt. Eine diesbezügliche Haftung ist jedoch erst ab dem Zeitpunkt der Kenntnis einer konkreten Rechtsverletzung möglich. Bei Bekanntwerden von entsprechenden Rechtsverletzungen werden wir diese Inhalte umgehend entfernen.


Haftung für Links

Unser Angebot enthält Links zu externen Webseiten Dritter, auf deren Inhalte wir keinen Einfluss haben. Deshalb können wir für diese fremden Inhalte auch keine Gewähr übernehmen. Für die Inhalte der verlinkten Seiten ist stets der jeweilige Anbieter oder Betreiber der Seiten verantwortlich. Die verlinkten Seiten wurden zum Zeitpunkt der Verlinkung auf mögliche Rechtsverstöße überprüft. Rechtswidrige Inhalte waren zum Zeitpunkt der Verlinkung nicht erkennbar. Eine permanente inhaltliche Kontrolle der verlinkten Seiten ist jedoch ohne konkrete Anhaltspunkte einer Rechtsverletzung nicht zumutbar. Bei Bekanntwerden von Rechtsverletzungen werden wir derartige Links umgehend entfernen.



Die durch die Seitenbetreiber erstellten Inhalte und Werke auf diesen Seiten unterliegen dem deutschen Urheberrecht. Die Vervielfältigung, Bearbeitung, Verbreitung und jede Art der Verwertung außerhalb der Grenzen des Urheberrechtes bedürfen der schriftlichen Zustimmung des jeweiligen Autors bzw. Erstellers. Downloads und Kopien dieser Seite sind nur für den privaten, nicht kommerziellen Gebrauch gestattet. Soweit die Inhalte auf dieser Seite nicht vom Betreiber erstellt wurden, werden die Urheberrechte Dritter beachtet. Insbesondere werden Inhalte Dritter als solche gekennzeichnet. Sollten Sie trotzdem auf eine Urheberrechtsverletzung aufmerksam werden, bitten wir um einen entsprechenden Hinweis. Bei Bekanntwerden von Rechtsverletzungen werden wir derartige Inhalte umgehend entfernen.